News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Discovery Laboratories to File Surfaxin Response in 4 Weeks
September 24, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Sept 24 (Reuters) - Discovery Laboratories Inc said it expects to submit a complete response to the U.S. Food and Drug Administration's concerns on its experimental lung drug for infants within the next four weeks.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Vaccines
FDA Pulls Valneva’s Chikungunya Shot From Market Citing ‘Serious Safety Concerns’
August 25, 2025
·
2 min read
·
Tristan Manalac
Regulatory
FDA To Publish Drug-Related Adverse Event Reports Daily
August 25, 2025
·
2 min read
·
Tristan Manalac
Tariffs
Trump Administration Settles on 15% Generic Drug Tariff Rate for EU
August 22, 2025
·
1 min read
·
Annalee Armstrong
Approvals
Ionis Wins Approval For First RNA-Targeted Prophylactic for Rare Swelling Disease
August 22, 2025
·
2 min read
·
Tristan Manalac